Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
2001 1
2002 1
2006 1
2008 2
2009 1
2011 1
2015 2
2016 1
2017 6
2018 7
2019 20
2020 21
2021 19
2022 19
2023 19
2024 21

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

122 results

Results by year

Filters applied: . Clear all
Page 1
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma.
Braun DA, Hou Y, Bakouny Z, Ficial M, Sant' Angelo M, Forman J, Ross-Macdonald P, Berger AC, Jegede OA, Elagina L, Steinharter J, Sun M, Wind-Rotolo M, Pignon JC, Cherniack AD, Lichtenstein L, Neuberg D, Catalano P, Freeman GJ, Sharpe AH, McDermott DF, Van Allen EM, Signoretti S, Wu CJ, Shukla SA, Choueiri TK. Braun DA, et al. Among authors: jegede oa. Nat Med. 2020 Jun;26(6):909-918. doi: 10.1038/s41591-020-0839-y. Epub 2020 May 29. Nat Med. 2020. PMID: 32472114 Free PMC article.
Risperidone-Associated Atrioventricular Block.
Jegede O, Taher K. Jegede O, et al. Am J Ther. 2019 Sep/Oct;26(5):e610-e612. doi: 10.1097/MJT.0000000000000810. Am J Ther. 2019. PMID: 29927774 No abstract available.
PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti-PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients.
Denize T, Jegede OA, Matar S, El Ahmar N, West DJ, Walton E, Bagheri AS, Savla V, Nabil Laimon Y, Gupta S, Vemula SV, Braun DA, Burke KP, Catalano PJ, Freeman GJ, Motzer RJ, Atkins MB, McDermott DF, Sharpe AH, Choueiri TK, Signoretti S. Denize T, et al. Among authors: jegede oa. Clin Cancer Res. 2024 Feb 16;30(4):803-813. doi: 10.1158/1078-0432.CCR-23-2274. Clin Cancer Res. 2024. PMID: 38060202 Free PMC article.
Identification of genetic subtypes in follicular lymphoma.
Shelton V, Detroja R, Liu T, Isaev K, Silva A, Passerini V, Bakhtiari M, Calvente L, Hong M, He MY, Modi S, Hershenfeld SA, Ludvigsen M, Madsen C, Hamilton-Dutoit S, d'Amore FA, Brodtkorb M, Johnson NA, Baetz T, LeBrun D, Tobin JWD, Gandhi MK, Mungall AJ, Xu W, Ben-Neriah S, Steidl C, Delabie J, Tremblay-LeMay R, Jegede O, Weigert O, Kahl B, Evens AM, Kridel R. Shelton V, et al. Among authors: jegede o. Blood Cancer J. 2024 Aug 7;14(1):128. doi: 10.1038/s41408-024-01111-w. Blood Cancer J. 2024. PMID: 39112453 Free PMC article.
Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL.
Smith MR, Jegede OA, Martin P, Till BG, Parekh SS, Yang DT, Hsi ED, Witzig T, Dave S, Scott D, Hanson C, Kostakoglu Shields L, Abdel-Samad N, Casulo C, Bartlett NL, Caimi PF, Al Baghdadi T, Blum KA, Romer MD, Inwards DJ, Lerner RE, Wagner LI, Little RF, Friedberg JW, Leonard JP, Kahl BS. Smith MR, et al. Among authors: jegede oa. Blood. 2024 Sep 5;144(10):1083-1092. doi: 10.1182/blood.2024023962. Blood. 2024. PMID: 38820500 Clinical Trial.
Chronic use of benzodiazepines: The problem that persists.
Louie DL, Jegede OO, Hermes GL. Louie DL, et al. Among authors: jegede oo. Int J Psychiatry Med. 2023 Sep;58(5):426-432. doi: 10.1177/00912174231166252. Epub 2023 Mar 27. Int J Psychiatry Med. 2023. PMID: 36972700 Review.
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B).
Atkins MB, Jegede OA, Haas NB, McDermott DF, Bilen MA, Stein M, Sosman JA, Alter R, Plimack ER, Ornstein MC, Hurwitz M, Peace DJ, Signoretti S, Denize T, Cimadamore A, Wu CJ, Braun D, Einstein D, Catalano PJ, Hammers H. Atkins MB, et al. Among authors: jegede oa. J Immunother Cancer. 2023 Mar;11(3):e004780. doi: 10.1136/jitc-2022-004780. J Immunother Cancer. 2023. PMID: 36948504 Free PMC article. Clinical Trial.
Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low-Tumor Burden Follicular Lymphoma.
Kahl BS, Jegede OA, Peterson C, Swinnen LJ, Habermann TM, Schuster SJ, Weiss M, Fishkin PA, Fenske TS, Williams ME. Kahl BS, et al. Among authors: jegede oa. J Clin Oncol. 2024 Mar 1;42(7):774-778. doi: 10.1200/JCO.23.01912. Epub 2024 Jan 9. J Clin Oncol. 2024. PMID: 38194625 Clinical Trial.
Buprenorphine Treatment of Fentanyl-Related Opioid Use Disorder.
Jegede O, Parida S, De Aquino JP. Jegede O, et al. Prim Care Companion CNS Disord. 2022 Apr 26;24(3):21cr03163. doi: 10.4088/PCC.21cr03163. Prim Care Companion CNS Disord. 2022. PMID: 35486939 Free article. No abstract available.
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214.
Mantia CM, Jegede OA, Plimack ER, Powles T, Motzer RJ, Tannir NM, Lee CH, Tomita Y, Voss MH, Choueiri TK, Rini BI, Hammers HJ, Escudier B, Albigès L, Rosenblatt L, Atkins MB, Regan MM, McDermott DF. Mantia CM, et al. Among authors: jegede oa. J Immunother Cancer. 2024 Jul 25;12(7):e009495. doi: 10.1136/jitc-2024-009495. J Immunother Cancer. 2024. PMID: 39060019 Free PMC article. Clinical Trial.
122 results